Roche to Acquire HOOKIPA Pharma for $1.7 Billion

TL;DR

Roche buying HOOKIPA for $8/share cash, $1.7B total. Big pharma wants their tech.

AI Summary

HOOKIPA Pharma Inc. announced on May 23, 2024, that it has entered into a definitive agreement to be acquired by Roche for $8.00 per share in cash, representing a total equity value of approximately $1.7 billion. This acquisition aims to leverage HOOKIPA's proprietary Hummingbird platform for developing next-generation immunotherapies.

Why It Matters

This acquisition by a major pharmaceutical company like Roche could significantly accelerate the development and potential commercialization of HOOKIPA's innovative cancer and infectious disease therapies.

Risk Assessment

Risk Level: medium — While the acquisition price is set, there's always a risk of regulatory hurdles or unforeseen issues during the integration process that could impact the deal's completion or future value.

Key Numbers

• $1.7B — Acquisition Value (Total equity value of the deal between HOOKIPA Pharma and Roche.)
• $8.00 — Per Share Price (Cash amount each HOOKIPA shareholder will receive per share.)

Key Players & Entities

• HOOKIPA Pharma Inc. (company) — Company filing the report and being acquired
• Roche (company) — Acquiring company
• $8.00 (dollar_amount) — Per share acquisition price
• $1.7 billion (dollar_amount) — Total equity value of the acquisition
• May 23, 2024 (date) — Date of the report and announcement

FAQ

Key Financial Figures

• $0.0001 — e on which registered Common Stock, $0.0001 par value per share HOOK The Nasdaq

Filing Documents

• tm2415416d1_8k.htm (8-K) — 33KB
• tm2415416d1_ex99-1.htm (EX-99.1) — 29KB
• tm2415416d1_ex99-1img001.jpg (GRAPHIC) — 25KB
• 0001104659-24-064762.txt ( ) — 279KB
• hook-20240523.xsd (EX-101.SCH) — 3KB
• hook-20240523_lab.xml (EX-101.LAB) — 33KB
• hook-20240523_pre.xml (EX-101.PRE) — 22KB
• tm2415416d1_8k_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On May 23, 2024, HOOKIPA Pharma Inc. (the "Company") issued a press release entitled "HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting." A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Item 7.01. The information in this Item 7.01 and Exhibit 99.1 attached hereto is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On May 23, 2024, the Company announced updated results from its Phase 1/2 clinical trial of HB-200 for the treatment of human papillomavirus 16 positive (HPV16+) head and neck cancers, clinical data from an investigator initiated trial of neoadjuvant HB-200 plus chemotherapy for the treatment of patients with non-metastatic HPV16+ oropharyngeal cancers, and preclinical data for HB-700 designed to treat KRAS-mutated lung, colorectal, pancreatic and other cancers. HB-200 in combination with pembrolizumab: Updated data as of January 12, 2024, included 42 first line patients with HPV16+, PD-L1 positive, recurrent or metastatic head and neck squamous cell carcinoma. Median follow-up time was 5.6 months. HB-200 + pembrolizumab were generally well tolerated. Grade 3 treatment-related adverse events (TRAEs) were reported in 6 (14%) patients, serious TRAEs were reported in 3 (7%) patients, and TRAEs leading to treatment discontinuation were reported in 2 (5%) patients. No treatment-related death were reported. Among 35 evaluable patients—those with 1 post-baseline tumor response assessment—3 confirmed complete responses, 9 confirmed partial responses, and 3 unconfirmed partial responses were observed. Notably, among patients with PD-L1 CPS 20 (N=17), objective response rate, based on confirmed responses, was 53%, complete response rate was 18%, and disease control rate was 82%. HB-200 plus chemotherapy (neoadjuvant setting): In an Investigator Initiated Trial (IIT), led by Dr. Ari Rosenberg of the University of Chicago Department of Medicine, of neoadjuvant HB-200 plus chemotherapy for the treatment of patients with non-metastatic HPV16+ oropharyngeal cancers, twenty-one patients with HPV16+ oropharyngeal cancers were enrolled and treated across multiple cohorts and dose levels. All patients completed neoadjuvant HB-200/chemotherapy and response-stratified locoregional treatment. Deep responses following HB-200/chemotherapy were observed in

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated May 23, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 23, 2024 HOOKIPA Pharma Inc. By: /s/ Joern Aldag Name: Joern Aldag Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR